Lygature

📢 𝗠𝗮𝗿𝗰𝗵 𝗶𝘀 𝗔𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗠𝗼𝗻𝘁𝗵!    Autoimmune diseases, such as Rheumatoid Arthritis and Inflammatory Bowel Disease (IBD), affect millions worldwide. These conditions fall under the umbrella of Immune-Mediated Inflammatory Diseases (IMIDs), which affect 5-7% of people in developed countries and include over 80 increasingly prevalent disorders.   ✨ That’s why Lygature is proud to support setting up the ImmuneHealthXL initiative. ImmuneHealthXL aims to achieve immune health for all, regardless of sex, ethnicity, or stage of life. By focusing on the underlying immunological processes rather than just individual diseases, this initiative will pave the way for new insights, better treatments, and improved quality of life for those affected by IMIDs including autoimmune diseases.   Together with ReumaNederland, Diabetes Fonds, Stichting MS Research, Hartstichting, MDL Fonds and the major leading academic medical centres of the Netherlands, Lygature is exploring the possibility of establishing a long term sustainable Public Private Partnership. The importance of patient impact is ensured by the participation of patient representatives from Crohn & Colitis NL and Vasculitis Stichting.   🔬 Why is this important? IMIDs may look different in every patient, but many share common immune system dysfunctions. A disease-overarching approach could lead to new breakthroughs in the research and treatment of IMIDs.    #AutoimmuneAwareness #IMIDs #ImmuneHealthXL #InnovationInHealth

Today is #WorldTBDay. We're proud to be a coordinating partner of UNITE4TB, the largest public-private partnership in Tuberculosis (TB) drug development in the history of the European Union. Lygature played an instrumental role in setting up UNITE4TB. Within the project we provide overall partnership management, co-lead the privacy and ethics work, and manage external communications. #YesWeCanEndTB #CommitInvestDeliver #GlobalHealth #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). Proud partner of the AMR Accelerator

Samenwerking met patiënten leidt tot betere innovaties.   Daar staan collega Laurence Maes, Lead Patient Value, en Heleen Knottnerus, Policy Officer Advocacy bij Diabetesvereniging Nederland volledig achter! Beide hebben in hun jarenlange ervaring gezien hoe samenwerking tussen geneesmiddelenbedrijven en patiënten het verschil kan maken in het verbeteren van geneesmiddelenontwikkeling.   “We kunnen het ons niet meer permitteren om niet samen te werken”.    Die urgentie is ook de reden om samen met verschillende geneesmiddelenbedrijven en patiëntenorganisaties in een partnerschap aan de slag te willen gaan met maatschappelijke vraagstukken. Het Lygature Live event was een mooie manier om dat vleugels te geven! Vereniging Innovatieve Geneesmiddelen

Great to see this milestone from the Lygature-coordinated Pediatric Praziquantel Consortium gaining media recognition—now also featured in C2W | Mens & Molecule and Devex! 🎉 More visibility helps raise awareness of this crucial advancement in global health. Read more here: 🔹 C2W (in Dutch): https://lnkd.in/enu2AiXq 🔹 Devex: https://lnkd.in/et-_nCpt #GlobalHealth #Schistosomiasis #BeatNTDs #HealthInnovation #PublicPrivatePartnership funded by the Global Health Innovative Technology (GHIT) Fund and the European & Developing Countries Clinical Trials Partnership (EDCTP). Lygature, in #Collaboration with Merck Group, Merck Healthcare, Astellas Pharma, Farmanguinhos / Fiocruz, Swiss Tropical and Public Health Institute, Unlimit Health (formerly SCI Foundation), Kenya Medical Research Institute (KEMRI), Ministry of Health, Kenya, Université Félix Houphouët-Boigny, Technical University of Munich, Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle (Côte d'Ivoire), African Institute for Health and Development, Makerere University, Ministry of Health - Uganda, Nutrition Division of the Ministry of Health - Uganda.

💬 Time for a chat to process the interesting talks and discussions about measuring impact of partnerships.   Connecting, sharing ideas and exploring new possibilities for impactful partnerships is a great way to end this year’s edition of Lygature LIVE.   We would like to thank all participants and speakers for attending Lygature LIVE 2025.   Thera Max-Mos (Central Committee on Research Involving Human Subjects (CCMO)) Heleen Knottnerus (Diabetesvereniging Nederland and EUPATI fellow) Laurence Maes (Johnson & Johnson Innovative Medicine) Chris De Jonghe (Oncode Institute) Hugh Laverty (Innovative Health Initiative (IHI))   Feel like you missed out or want to stay updated on Lygature’s partnerships? Sign up to our newsletter: https://lnkd.in/esqc72RW

Managing Director of Lygature, Jorg Janssen got Lygature LIVE on the road. While Lygature's Program Manager Vera Nies explained about the various definitions of impact of partnerships.   We can’t wait to hear the many other inspiring talks and participate in discussions about different perspectives on impactful partnerships.   #publicprivatepartnerships #impact

Preparations for Lygature LIVE are in full swing.   Join us today for Lygature LIVE at Villa Jongerius in Utrecht.   Doors open at 14:30 and the program starts at 15:00.   Lygature LIVE will highlight impactful partnerships and explore methods for determining and measuring their impact on society and global well-being.   We look forward to seeing you shortly!   #publicprivatepartnerships #impact

Great to have our colleague Sophie Huiskes-Berends representing the Regulatory Science Network Netherlands at the DIA Europe Conference 2025 today! At Lygature, we believe partnerships are key to solving modern health challenges. The RSNN is a good example of a such a partnership, contributing to a more effective and efficient regulatory system. #DIAEUROPE2025 #partnerships #regulatory #regulatoryscience

⌛ Last chance to register for Lygature LIVE   Only a couple of days left until Lygature goes live on March 19, 2025 at Villa Jongerius in Utrecht.   🌍 Lygature LIVE will highlight impactful partnerships and explore methods for determining and measuring their impact on society and global well-being.   Join us to discuss impactful partnerships and hear inspiring speakers: - Thera Max-Mos (Central Committee on Research Involving Human Subjects (CCMO)) will speak on the role of CCMO in the regulatory field, and on the added value of the Regulatory Science Network Netherlands to meet and engage with regulatory stakeholders. - Heleen Knottnerus (Diabetesvereniging Nederlandand EUPATI fellow) and Laurence Maes (Johnson & Johnson Innovative Medicine) will address boosting the impact of patient involvement in drug discovery. - Chris De Jonghe (Oncode Institute) will speak on the impact of Oncode Institute and the advantages of its connection with Lygature. - Hugh Laverty (Innovative Health Initiative (IHI)) will share his thoughts on measuring the impact and value of the project portfolios of the IMI and IHI initiatives.   💬 And connect with us afterwards during the networking drinks and dinner.   Register now to secure one of the last spots 👉 https://lnkd.in/eHVnKSCE #impact #publicprivatepartnerships #partnerships #event

At Lygature, we believe that collaboration is the key to advancing medical innovations. As highlighted by our Managing Director, Jorg Janssen, in his interview in today's edition of Trouw, genuine partnerships are what truly drive impact. Jorg spoke about the recent milestone achieved by the Lygature-coordinated Pediatric Praziquantel Consortium: the first preschool-aged children have now been treated with the Consortium's new pediatric formulation for schistosomiasis. This milestone is a testament to the power of working together toward meaningful healthcare solutions. Let’s continue to build strong partnerships that make a real difference! Read more in Trouw (article in Dutch) - link in the comments. Photo credit: Kibuuka Makisa/Candid Local #GlobalHealth #Schistosomiasis #BeatNTDs #SDGs #HealthInnovation #PublicPrivatePartnership funded by the Global Health Innovative Technology (GHIT) Fund and the European & Developing Countries Clinical Trials Partnership (EDCTP).    In collaboration with: Merck Group, Merck Healthcare, Astellas Pharma, Farmanguinhos / Fiocruz, Swiss Tropical and Public Health Institute, Unlimit Health (formerly SCI Foundation), Kenya Medical Research Institute (KEMRI), Ministry of Health, Kenya, Université Félix Houphouët-Boigny, Technical University of Munich, Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle (Côte d'Ivoire), African Institute for Health and Development, Makerere University, Ministry of Health - Uganda, Nutrition Division of the Ministry of Health - Uganda.